S&P 500   4,288.05 (-0.27%)
DOW   33,507.50 (-0.47%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.35%)
BABA   86.75 (+1.41%)
AMD   102.82 (+0.06%)
T   15.03 (+0.13%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.69%)
GE   110.55 (-1.59%)
DIS   81.06 (+1.16%)
AMC   7.99 (+2.57%)
PFE   33.18 (+3.40%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
S&P 500   4,288.05 (-0.27%)
DOW   33,507.50 (-0.47%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.35%)
BABA   86.75 (+1.41%)
AMD   102.82 (+0.06%)
T   15.03 (+0.13%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.69%)
GE   110.55 (-1.59%)
DIS   81.06 (+1.16%)
AMC   7.99 (+2.57%)
PFE   33.18 (+3.40%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
S&P 500   4,288.05 (-0.27%)
DOW   33,507.50 (-0.47%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.35%)
BABA   86.75 (+1.41%)
AMD   102.82 (+0.06%)
T   15.03 (+0.13%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.69%)
GE   110.55 (-1.59%)
DIS   81.06 (+1.16%)
AMC   7.99 (+2.57%)
PFE   33.18 (+3.40%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
S&P 500   4,288.05 (-0.27%)
DOW   33,507.50 (-0.47%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.35%)
BABA   86.75 (+1.41%)
AMD   102.82 (+0.06%)
T   15.03 (+0.13%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.69%)
GE   110.55 (-1.59%)
DIS   81.06 (+1.16%)
AMC   7.99 (+2.57%)
PFE   33.18 (+3.40%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
NASDAQ:ATHX

Athersys (ATHX) Stock Forecast, Price & News

$0.43
+0.07 (+19.33%)
(As of 09/29/2023 ET)
Compare
Today's Range
$0.38
$0.45
50-Day Range
$0.28
$0.80
52-Week Range
$0.26
$2.76
Volume
839,180 shs
Average Volume
274,411 shs
Market Capitalization
$9.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.50

Athersys MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,172.9% Upside
$5.50 Price Target
Short Interest
Healthy
3.62% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.34mentions of Athersys in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.88 out of 5 stars


ATHX stock logo

About Athersys (NASDAQ:ATHX) Stock

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. The company was founded in 1995 and is headquartered in Cleveland, Ohio.

ATHX Price History

ATHX Stock News Headlines

StockNews.com Initiates Coverage on Athersys (NASDAQ:ATHX)
Successful Options Trading Begins With…
Options trading expert Wendy Kirkland’s free guide reveals the options trading principles that are as easy to implement as they are to learn and how using them could earn you thousands in extra income each month!
Is Athersys Inc (ATHX) Significantly Overvalued?
Why Is Athersys (ATHX) Stock Down 36% Today?
Successful Options Trading Begins With…
Options trading expert Wendy Kirkland’s free guide reveals the options trading principles that are as easy to implement as they are to learn and how using them could earn you thousands in extra income each month!
Athersys (NASDAQ: ATHX)
Athersys Restructures Debt with Supplier
See More Headlines
Receive ATHX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Athersys and its competitors with MarketBeat's FREE daily newsletter.

ATHX Company Calendar

Last Earnings
8/16/2023
Today
9/29/2023
Next Earnings (Estimated)
11/13/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ATHX
Employees
24
Year Founded
1995

Price Target and Rating

Average Stock Price Forecast
$5.50
High Stock Price Forecast
$5.50
Low Stock Price Forecast
$5.50
Forecasted Upside/Downside
+1,207.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-72,530,000.00
Net Margins
-1,362.14%
Pretax Margin
-32,469.17%

Debt

Sales & Book Value

Annual Sales
$5.32 million
Book Value
($1.33) per share

Miscellaneous

Free Float
22,494,000
Market Cap
$9.46 million
Optionable
Optionable
Beta
-0.74

Social Links

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Mr. Daniel A. Camardo M.B.A. (Age 54)
    CEO, Sec., Principal Accounting Officer & Director
    Comp: $796.81k
  • Ms. Z. Kasey Rosado (Age 49)
    Interim Chief Financial Officer
    Comp: $1.51M
  • Ms. Maia A. Hansen M.B.A. (Age 54)
    M.S., Chief Operating Officer
    Comp: $962.57k
  • Senthil Ranganathan Ph.D.
    VP of Technical Operations
  • Mr. David Russ M.B.A.
    VP of Supply Chain, Fin. & Admin.
  • Dr. Manal Morsy M.B.A.
    M.D., PH.D., Exec. VP & Head of Global Regulatory Affairs
  • Dr. Robert Mays Ph.D.
    Exec. VP, Head of Regenerative Medicine & Neuroscience Programs
  • Mr. Rakesh Ramachandran MS
    Head of Information Technology & Communications and VP
  • Dr. Sarah Busch Ph.D.
    VP of Regenerative Medicine & Head of Bus. Devel.
  • Ms. Ellen Gurley
    Mang. of Corp. Communications and Investor Relations













ATHX Stock - Frequently Asked Questions

Should I buy or sell Athersys stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Athersys in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ATHX shares.
View ATHX analyst ratings
or view top-rated stocks.

What is Athersys' stock price forecast for 2023?

1 analysts have issued 12-month target prices for Athersys' stock. Their ATHX share price forecasts range from $5.50 to $5.50. On average, they expect the company's stock price to reach $5.50 in the next twelve months. This suggests a possible upside of 1,207.7% from the stock's current price.
View analysts price targets for ATHX
or view top-rated stocks among Wall Street analysts.

How have ATHX shares performed in 2023?

Athersys' stock was trading at $0.84 at the start of the year. Since then, ATHX shares have decreased by 49.9% and is now trading at $0.4206.
View the best growth stocks for 2023 here
.

When is Athersys' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our ATHX earnings forecast
.

How were Athersys' earnings last quarter?

Athersys, Inc. (NASDAQ:ATHX) announced its earnings results on Wednesday, August, 16th. The biopharmaceutical company reported ($0.62) EPS for the quarter. The biopharmaceutical company earned $0.05 million during the quarter.

When did Athersys' stock split?

Shares of Athersys reverse split on the morning of Monday, August 29th 2022. The 1-25 reverse split was announced on Monday, August 29th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What is William (B.J.) Lehmann's approval rating as Athersys' CEO?

1 employees have rated Athersys Chief Executive Officer William (B.J.) Lehmann on Glassdoor.com. William (B.J.) Lehmann has an approval rating of 100% among the company's employees. This puts William (B.J.) Lehmann in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 65.0% of employees surveyed would recommend working at Athersys to a friend.

What other stocks do shareholders of Athersys own?
What is Athersys' stock symbol?

Athersys trades on the NASDAQ under the ticker symbol "ATHX."

How do I buy shares of Athersys?

Shares of ATHX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Athersys' stock price today?

One share of ATHX stock can currently be purchased for approximately $0.42.

How much money does Athersys make?

Athersys (NASDAQ:ATHX) has a market capitalization of $9.46 million and generates $5.32 million in revenue each year. The biopharmaceutical company earns $-72,530,000.00 in net income (profit) each year or ($3.03) on an earnings per share basis.

How can I contact Athersys?

Athersys' mailing address is 3201 CARNEGIE AVENUE, CLEVELAND OH, 44115. The official website for the company is www.athersys.com. The biopharmaceutical company can be reached via phone at (216) 431-9900, via email at ir@athersys.com, or via fax at 216-361-9495.

This page (NASDAQ:ATHX) was last updated on 9/29/2023 by MarketBeat.com Staff

My Account -